Exploratory research investigating the impact on the respose rate, prognosis, quality of life, and organ preservation after the total neoaduvant therapy with chemoradiation followed by chemotherapy (CapeOX) for locally advanced rectal cancer. - R-NAC02

Taketomi Akinobu0 个研究点目标入组 55 人开始时间: 2022年9月27日最近更新: 2023年10月17日

试验速览

暂无简介。

•1. The cases histologically diagnosed as rectal adenocarcinoma by endoscopic biopsy.
•2. clinical stage II-III by preoperative imaging.
•3. The main occupation of the primary tumor site is located middle and lower rectum. (within 12 cm from anal verge)
•4. The age is 20 years old and older and under 75 years old.
•5. Performance Status(ECOG) is 0 or 1.
•6. No history of surgical treatment for primary tumor.
•7. Cases without a history of chemotherapy and radiation.
•8. Cases of major organ function is maintained.
•9. Cases of childbearing potential must consent to the contraception (female, from the consent to 7 weeks after the last chemotherapy; male, from the consent to 15 weeks after the last chemotherapy).
•10. Cases with written informed concent.

•1. Double cancer
•2. Pregnant or lactating women.
•3. Cases with a history of colorectal cancer (Excluding mucosal cancer).
•4. Cases with peripheral sensory neuropathy(CTCAE v5.0 Grade 1 or more).
•5. Cases with infectious disease requiring systemic therapy.
•6. Cases with uncontrolable cardiovascular disease.
•7. Cases with a history of mental disorder.
•8. HBs-Ag positive, HIV1-Ab positive, HIV2-Ab positive, HTLV1-Ab positive, HCV-Ab positive, HBc-Ab positive with HBV-DNA positive, or HBs-Ab positive with HBV-DNA positive
•9. Cases whom the investigators judged as inappropreate for some reasons

发起方

Taketomi Akinobu